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Phosphorylation of the skeletal muscle (RyR1) and
cardiac muscle (RyR2) ryanodine receptors has been
reported to modulate channel activity. Abnormally high
phosphorylation levels (hyperphosphorylation) at Ser-
2843 in RyR1 and Ser-2809 in RyR2 and dissociation of
FK506-binding proteins from the receptors have been
implicated as one of the causes of altered calcium home-
ostasis observed during human heart failure. Using site-
directed mutagenesis, we prepared recombinant RyR1
and RyR2 mutant receptors mimicking constitutively
phosphorylated and dephosphorylated channels carry-
ing a Ser/Asp (RyR1-S2843D and RyR2-S2809D) and Ser/
Ala (RyR1-S2843A and RyR2-S2809A) substitution, re-
spectively. Following transient expression in human
embryonic kidney 293 cells, the effects of Ca2, Mg2,
and ATP on channel function were determined using
single channel and [3H]ryanodine binding measure-
ments. In both assays, neither the skeletal nor cardiac
mutants showed significant differences compared with
wild type. Similarly essentially identical caffeine re-
sponses were observed in Ca2 imaging measurements.
Co-immunoprecipitation and Western blot analysis
showed comparable binding of FK506-binding proteins
to wild type and mutant receptors. Finally metabolic
labeling experiments showed that the cardiac ryano-
dine receptor was phosphorylated at additional sites.
Taken together, the results did not support the view
that phosphorylation of a single site (RyR1-Ser-2843 and
RyR2-Ser-2809) substantially changes RyR1 and RyR2
channel function.
Contraction of striated muscle is induced by the release of
Ca2 from the sarcoplasmic reticulum (SR)1 in a series of signal
transduction steps known as excitation-contraction coupling.
SR Ca2 release is initiated by an action potential on the
surface membrane that activates SR calcium release channels
also known as ryanodine receptors (RyRs). In mammalian skel-
etal muscle, this process is mediated by a direct physical inter-
action between voltage-gated, dihydropyridine-sensitive Ca2
channels located in the surface membrane and transverse tu-
bular infoldings (t-tubules) and the skeletal muscle RyR (RyR1)
(1). In mammalian myocardium, an action potential initiates
cardiac ryanodine receptor (RyR2) activation and SR Ca2
release by a mechanism referred to as calcium-induced calcium
release (2). During calcium-induced calcium release, the influx
of Ca2 ions through voltage-gated, dihydropyridine-sensitive
Ca2 channels triggers the massive release of Ca2 from the
SR by activating a group of closely opposed RyR2s (3).
Modulation of skeletal and cardiac excitation-contraction
coupling results, in part, from changes in the phosphorylation
state of numerous SR proteins involved in Ca2 homeostasis.
One of these proteins has been suggested to be the ryanodine
receptor. RyR1 and RyR2 belong to a family of ligand-gated ion
channels composed of four large subunits with molecular
masses of 565 kDa with each subunit being associated with
one small 12- and 12.6-kDa FK506-binding protein (FKBP12
and -12.6), respectively (4, 5). The FKBPs belong to the family
of immunophilins, exhibit cis/trans isomerase activity, and
have been reported to stabilize channel protein conformation
and synchronize the gating of neighboring RyRs (coupled gat-
ing) (6–8). RyR1 and RyR2 are part of a multiprotein complex
that includes cAMP-dependent protein kinase (PKA), protein
phosphatase 1, and muscle protein kinase A-anchoring protein
(9). The RyR2 complex also contains and is regulated by protein
phosphatase 2A (9, 10). Although isoform-specific differences
are observed, the skeletal and cardiac ryanodine receptors are
regulated by a common group of endogenous ligands including
Ca2, Mg2, ATP, and calmodulin (5, 11).
Initially RyR2 was proposed to have a unique phosphoryla-
tion site (RyR2-Ser-2809) for Ca2/calmodulin-dependent ki-
nase II (CaMKII). The site was also phosphorylated by PKA but
to a lesser extent (12). Although initial studies found that the
homologous site in skeletal RyR (RyR1-Ser-2843) was not phos-
phorylated by CaMKII (12), other studies have observed in
vitro CaMKII phosphorylation of this site and additional thre-
onine residue(s) (13, 14). Different functional effects following
CaMKII and PKA phosphorylation also indicated the presence
of additional phosphorylation sites (15). Metabolic labeling of
RyR2 provided direct evidence for additional phosphorylation
sites by showing that CaMKII phosphorylates at least four
additional sites in RyR (16). In support of a physiological role,
CaMKII co-purified with cardiac muscle RyR (17) and, in skel-
etal SR vesicles, remained anchored to RyR in lipid bilayer
measurements, altering the regulation of channel activity by
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ATP and Ca2 (18). In skeletal muscle, KAP, a non-kinase
protein, has been identified as one of the anchoring proteins
necessary for targeting the CaMKII holoenzyme to the SR
membrane (19).
In single channel measurements, PKA-mediated phosphoryl-
ation of RyR decreased ATP and Mg2 sensitivity, and the
phosphorylated RyR channels exhibited an increase in the
number of channel events and mean open time (20) and altered
the Ca2 sensitivity under non-steady-state conditions (21). In
failing hearts, release of protein phosphatases from the RyR2
protein complex has been suggested to increase the endogenous
PKA-mediated phosphorylation levels of RyR2 (“hyperphos-
phorylation”) (9). Recently hyperphosphorylation and FKBP12
depletion of the skeletal ryanodine receptor during heart dis-
ease have been described and linked to the severely decreased
exercise capability observed in these patients (22). Failing to
observe dissociation of protein phosphatase 1, the only phos-
phatase known to associate with RyR1, during heart failure
indicates a novel mechanism for PKA-mediated hyperphospho-
rylation of RyR1 in skeletal muscle (23). In both RyR1 and
RyR2, hyperphosphorylation of the receptor was accompanied
by an almost complete elimination of FKBP12 and FKBP12.6
binding to the receptor (9, 23). Loss of FKBP was proposed to
increase RyR sensitivity to the agonist Ca2 and thereby in-
crease SR Ca2 “leakiness” at diastolic Ca2 levels (9, 23, 24).
Other studies failed to establish a role for PKA-mediated phos-
phorylation on RyR activity (25, 26).
To investigate the functional effects of RyR phosphorylation
in more detail, we prepared recombinant RyR1 and RyR2 phos-
phorylation mutants that cannot be phosphorylated at their
known phosphorylation site, RyR1-Ser-2843 and RyR2-Ser-
2809, due to an alanine or aspartic acid substitution. These
amino acid substitutions mimic a constitutively dephosphoryl-
ated and phosphorylated receptor state, respectively. Func-
tional and biochemical effects of these mutations were assessed
using [3H]ryanodine binding, single channel, and calcium im-
aging measurements as well as co-immunoprecipitation. The
results presented here suggest that ryanodine receptors may be
phosphorylated at additional site(s) in vivo and that phospho-
rylation of RyR1-Ser-2843 and RyR2-Ser-2809, per se, does not
cause major functional changes.
EXPERIMENTAL PROCEDURES
Materials—Phospholipids were obtained from Avanti Polar Lipids
(Birmingham, AL). [3H]Ryanodine and [32P]PO4
3 were purchased from
PerkinElmer Life Sciences and ICN Biomedicals Inc. (Costa Mesa, CA),
respectively. FK506 was generously provided by Dr. Bekershy, Fuji-
sawa Healthcare Inc., Deerfield, IL. All chemicals used were of analyt-
ical grade.
Site-directed Mutagenesis and Cell Culture—The full-length rabbit
RyR1 cDNA was constructed as described previously (27). Full-length
rabbit RyR2 was kindly provided by Dr. Junichi Nakai, National Insti-
tute of Physiological Science, Okazaki, Japan. cDNAs encoding RyR1-
S2843A and -S2843D and RyR2-S2809A and -S2809D mutants were
prepared using Pfu polymerase-based chain reaction and the
QuikChange site-directed mutagenesis kit according to the manufac-
turer’s instructions (Stratagene, La Jolla, CA). The sequences of the
primers used for mutagenesis were as follows: RyR1-S2843A, g aca cgg
aag att Gcc cag act gcc cag; RyR1-S2843D, g aaa aag aca cgg aag att GAc
cag act gcc cag acc tac; RyR2-S2809A, ga act cgt cgt att Gct cag aca agc
cag g; RyR2-S2809D, cc ctt tat aac cga act cgt cgt att GAt cag aca agc c.
The PvuI/NdeI (positions 8600–11304) fragment of RyR1 cDNA and the
MunI/XbaI (positions 7736–10066) fragment of RyR2 subcloned into
vector served as the template for mutagenesis. The complete mutated
sequences were confirmed by DNA sequencing. The RyR1 mutated
sequence was subcloned back into the original position of RyR1 in two
steps: to a vector containing PvuI/XbaI (positions 8600–15276) frag-
ment and preparation of mutated RyR1 full-length plasmids by ligation
of two fragments (ClaI/PvuI and PvuI/XbaI containing the mutated
sequence) and pCMV5 (ClaI/XbaI). The RyR2 fragment with the muta-
tion was subcloned back into the original position of RyR2 in two steps:
to a vector containing BbrPI/SacII (positions 5038–11203) fragment
and to full-length RyR2 in pCIneo. Nucleotide numbering is as de-
scribed previously (27, 28).
WT and mutant RyRs were transiently expressed, in the presence of
FKBP12.6 where indicated, in HEK293 cells using FuGENE 6 (Roche
Applied Science) according to the manufacturer’s instructions. Cells
were maintained at 37 °C and 5% CO2 in high glucose Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine serum and plated
the day before transfection. For each 10-cm culture dish, 3.5 g of cDNA
was used. Cells were harvested 48 h after transfection. Crude mem-
brane fractions were prepared as described previously (27) and stored
under liquid nitrogen until use.
Preparation of SR Vesicles—SR vesicle fractions enriched in [3H]ry-
anodine binding were prepared from rabbit skeletal and canine cardiac
muscle in the presence of protease inhibitors (100 nM aprotinin, 1 M
leupeptin, 1 M pepstatin, 1 mM benzamidine, 0.2 mM phenylmethyl-
sulfonyl fluoride) (29, 30).
Single Channel Measurements—Single channel measurements were
performed in symmetric KCl solutions (250 mM, 20 mM KHepes, pH 7.4)
containing additions as indicated (31). Membrane fractions containing
the WT and mutant receptors were added to the cis chamber of a bilayer
apparatus and fused in the presence of an osmotic gradient with Muel-
ler-Rudin type planar bilayers containing a 5:3:2 mixture of bovine
brain phosphatidylethanolamine, phosphatidylserine, and phosphati-
dylcholine (35 mg of total phospholipid/ml n-decane). The gradient was
formed across the bilayer membrane with 250 mM cis KCl and 20 mM
trans KCl solutions. After appearance of single channel activity, an
increase in trans KCl concentration to 250 mM prevented further incor-
poration of RyRs. The trans side of the bilayer was defined as ground.
Channel activities were recorded at 20 mV and with 10 mM Ca2 in
the trans chamber at 0-mV holding potential using a commercially
available patch clamp amplifier with a bilayer headstage (Axopatch 1D,
Axon Instruments, Burlingame, CA). Measurement of the sensitivity of
the channels to cytosolic Ca2 indicated that in a majority of recordings
(98%) the cytosolic side of RyRs faced the cis side and the luminal side
faced the trans side of the bilayer. Electrical signals were filtered at 2
kHz or 300 Hz with K and Ca2 as current carrier, respectively, and
digitized at 10 kHz. Data acquisition and analysis were performed with
the software package pClamp 9.0.2. (Axon Instruments, Union City,
CA). Data files were directly acquired using the continuous gap-free
mode. Channel parameters were calculated from current recordings of
2-min duration using a threshold setting of 50% of the current ampli-
tude between the closed and open states. Channel open probability (Po)
in multichannel recordings was calculated using the formula  iPo,i/N
where N is the total number of channels, and Po,i is channel open
probability of the ith channel. The presence of possible substates rela-
tive to the full-open amplitude was probed using current amplitude
histograms obtained from 2-min single channel recordings.
[3H]Ryanodine Binding—Ryanodine binds with high specificity to
the RyRs and is widely used as a probe of channel activity because of its
preferential binding to the open channel state (4, 32). Unless otherwise
indicated, experiments were performed as described previously (33).
Membrane fractions (25–75 g of protein in 120 l of total sample
volume) were incubated with 2.5 nM [3H]ryanodine in 10 mM imidazole,
pH 7.0 buffer containing 150 mM KCl, 0.3 M sucrose, under oxidizing (1
mM oxidized glutathione, GSSG) or reducing (5 mM reduced glutathi-
one, GSH) conditions, and the indicated additions of channel agonists
and/or antagonists. After 24 h at room temperature, samples were
diluted with 8.5 volumes of ice-cold water and placed on Whatman GF/B
filters preincubated with 2% polyethylenimine in water. Radioactivity
remaining on the filters was determined by liquid scintillation counting
to obtain bound [3H]ryanodine. Nonspecific binding was determined
using a 1000-fold excess of unlabeled ryanodine in the presence of 1 mM
EGTA. The total number of ryanodine binding sites (Bmax) was deter-
mined in 10 mM imidazole, pH 7.0 buffer containing 800 mM KCl, 200
M free Ca2 by Scatchard plot analysis or at 30 nM [3H]ryanodine, a
condition that caused maximal binding of [3H]ryanodine to the recep-
tors. If not stated differently, data were normalized using Bmax values.
In experiments using protein phosphatase-treated SR, acid phospha-
tase (Sigma) was dialyzed for 5 h at 4 °C against sample buffer, and
membranes were subsequently incubated with phosphatase at 60 g of
protein/unit of protein phosphatase for 1 h at 37 °C. RyR2-Ser-2809
phosphorylation levels of treated and untreated samples were deter-
mined by immunoblot analysis using a phospho-RyR2-Ser-2809- and
dephospho-RyR2-Ser-2809-specific antibody (Badrilla, Leeds, UK). De-
velopment and analysis of Western blots were performed as described
under “Co-immunoprecipitation of RyRs and FKBPs” except that 5%
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bovine serum albumin in Tris-buffered saline was used for blocking and
primary antibody incubation medium, and Tris-buffered saline with
0.05% Tween 20 was used as washing buffer.
Co-immunoprecipitation of RyRs and FKBPs—For immunoprecipi-
tation experiments, membranes (1–2 mg of protein) were homogenized
in ice-cold 20 mM NaPipes, pH 7.2 buffer containing 0.3 M sucrose, 1 M
NaCl, 2.5% Triton X-100, and protease inhibitors (Complete choice
protease inhibitor tablets, Roche Applied Science) using a Teflon ho-
mogenizer. Following a 10-min incubation on ice, samples were diluted
with ice-cold water to 1.25% Triton X-100 and incubated on ice for an
additional 20 min. Solubilized receptors were separated by centrifuga-
tion at 100,000  g for 40 min, diluted with 20 mM NaPipes, pH 7.0
buffer containing 0.3 M sucrose, 5 mM dithiothreitol, 1.2 mM CaCl2, and
protease inhibitors to 0.3% Triton X-100 and 125 mM NaCl, and incu-
bated with mouse monoclonal antibody RyRD110 (1:10) raised against
rabbit skeletal muscle RyR and mouse monoclonal antibody RyRC3-33
(1:10) raised against cardiac muscle RyR at 4 °C. After 12 h, anti-mouse
IgG-agarose beads (Sigma) were added, and the sample was incubated
for an additional 2 h. Subsequently beads were washed three times with
20 mM NaPipes, pH 7.0 buffer containing 0.3% Triton X-100 and 125 mM
NaCl and once with phosphate-buffered saline (PBS) to remove residual
Triton X-100. Bound proteins were solubilized in SDS buffer at 37 °C for
15 min and separated on 3–15% gradient SDS-polyacrylamide gels.
Proteins in the top half of the gel (60 kDa) were transferred in a cooled
wet chamber for 1 h at 400 mA and 12 h at 1000 mA onto a polyvinyli-
dene difluoride membrane (Millipore) and blocked with 5% milk and
0.05% Tween 20 in PBS. RyRs were detected using monoclonal antibody
RyRD110 and monoclonal antibody RyRC3-33, both diluted to 1:10 with
5% milk and 0.05% Tween 20 in PBS. The bottom half of the gel was
transferred in a semidry chamber overnight at 50 mA onto polyvinyli-
dene difluoride, blocked with 5% milk and 0.05% Tween 20 in PBS, and
blotted with anti-FKBP antibody (Alexis) diluted to 1:2000 in 5% milk
and 0.05% Tween 20 in PBS. RyR and co-immunoprecipitated FKBP
were detected using enhanced chemiluminescence (ECL) (Amersham
Biosciences), and proteins were quantified using Kodak Scientific Im-
aging Systems 1D version 3.6 software.
Calcium Imaging—Cellular Ca2 release in response to caffeine was
determined by intracellular fluo-4 fluorescence. HEK293 cells trans-
fected with cDNA encoding WT and mutant RyRs were grown on glass
coverslips. RyR2 cDNAs were co-transfected with FKBP12.6 cDNA. For
control experiments, non-transfected cells or cells transfected with vec-
tor-only plasmids were used. Calcium imaging experiments were per-
formed similarly to those described in Ref. 34. Approximately half-
confluent cells were loaded with 5 M fluo-4 ester, 0.1% dispersion
agent (F-127) at 37 °C in Krebs-Ringer-Henseleit solution (KRH) con-
taining 125 mM NaCl, 5 mM KCl, 1.2 mM KH2PO4, 6 mM glucose, 1.2 mM
MgCl2, 2 mM CaCl2, and 25 mM Hepes, pH 7.4. After 1 h, cells were
rinsed with KRH to remove non-hydrolyzed fluorophore and trans-
ferred to a chamber. The fluorescence response was measured using a
Nikon Eclipse TE300 microscope and Photon Technology International
Deltascan system. Fluo-4 was excited at 490 nm, and emitted fluores-
cence was recorded at 526 nm. Base-line fluorescence was adjusted to
30–40 response units and recorded for 30 s, and caffeine responsiveness
of cells was measured by rapid (1-s) addition of freshly made caffeine
solution to a final concentration of 10 mM. Preliminary experiments
indicated that this concentration was sufficient to result in maximal
caffeine response. To allow normalization, cells were subsequently
treated with ionomycin to measure fluorescence in the presence of 2 mM
Ca2. For analysis, individual cells were defined as regions of interest,
and average fluorescence was quantified using the program ImageMas-
ter (Photon Technology International). Background levels were sub-
tracted, and responsiveness was normalized using the analysis program
Felix (Photon Technology International).
Metabolic Labeling of RyR2—In metabolic labeling experiments, 2–
3  107 HEK293 cells were used. To increase the extent of metabolic
32Pi labeling, cells were incubated for 1 h in phosphate-free Dulbecco’s
modified Eagle’s medium prior to labeling for 12 h in fresh phosphate-
free medium supplemented with 100 Ci/ml 32Pi (ICN Biomedicals
Inc.). PBS and all other buffers used for harvesting and processing the
cells contained Complete choice protease inhibitor tablets (Roche Ap-
plied Science) and phosphatase inhibitor mixture I (Sigma), 1 mM
Na3VO4, and 75 mM Na3PO4. Crude membrane fractions from metabol-
ically labeled HEK293 cells were solubilized in 20 mM NaPipes, pH 7.4
buffer containing 0.3 M sucrose, 2.5% Triton X-100, and 1 M NaCl.
Extended solubilization times of 4 h were required before affinity pu-
rification to eliminate a 32P-labeled high molecular weight band trav-
eling closely above the RyR on the gels. Following dilution to 0.3%
Triton X-100 and 125 mM NaCl, RyR2 was purified by binding to
CaM-agarose beads in the presence of 900 M free Ca2 and 3 mM
dithiothreitol. Following washing of the beads, proteins were separated
by 3–10% SDS-PAGE. Gels were silver-stained and dried using a gel
drying solution (Invitrogen), and the incorporation of 32Pi was visual-
ized using phosphorimaging (Storm PhosphorImager, ImageQuant
analysis software, and general purpose screens, all obtained from Am-
ersham Biosciences). In parallel experiments, unlabeled cells were pro-
cessed identically. The position of RyR2 as determined by Western blot
analysis was used to identify the silver-stained RyR2 bands in the
32Pi-labeled gels and PhosphorImager scans. To quantify the amount of
32Pi incorporation, identically sized gel pieces containing the RyR2 band
were incubated with scintillation fluid for 24 h and counted using a
scintillation counter. To account for potential differences in initial 32Pi
uptake by the cells, 32P content of a second gel piece at 200-kDa
molecular mass was determined and used to normalize the RyR2 signal.
Background signal intensities of non- and vector-only-transfected cells
were determined and subtracted from all samples, and final results
were adjusted for RyR2 protein content based on signal intensity in
silver-stained gels and Western blots. Western blot and silver stain
gave consistent data regarding the RyR2 protein content.
Determination of Free Ca2 Concentrations—Different free Ca2 con-
centrations were prepared by mixing CaCl2 and EGTA as determined
using the stability constants and computer program published previ-
ously (35). Free Ca2 concentrations of 1 M were verified with the use
of a Ca2-selective electrode (detectION, Philadelphia, PA), and those of
1 M were determined using fluo-3.
Data Analysis—Results are given as means 	 S.E. with the number
of experiments in parentheses. Significance of differences in the data
(p  0.05) was determined using Student’s t test.
RESULTS
We used site-directed mutagenesis to prepare skeletal and
cardiac RyR mutants that carry an alanine or aspartic acid
substitution at the conserved phosphorylation site, RyR1-Ser-
2843 and RyR2-Ser-2809. To investigate channel characteris-
tics in the absence of an endogenous receptor population, re-
combinant WT and mutant RyRs were transiently expressed in
HEK293 cells. In this cell line, absence of an endogenous RyR
pool was confirmed by (i) reverse transcriptase PCR in which
no skeletal or cardiac RyR mRNAs were detected, (ii) lack of an
RyR immunoblot signal in Western blots, and (iii) failure to
observe a functional response in [3H]ryanodine binding and
calcium imaging experiments (data not shown). Reverse tran-
scriptase PCR experiments indicated that both FKBP12 and
-12.6 mRNA were present in HEK293 cells with FKBP12
mRNA being more abundant. Similarly we found that in im-
munoblots the expression level of FKBP12 exceeded that of
FKBP12.6 (data not shown).
RyR expression levels were determined by Scatchard plot
analysis. Transfection using RyR1 cDNA resulted in expression
levels of 0.1–0.2 pmol/mg of protein as determined by [3H]ry-
anodine binding; cardiac RyR expressional levels were 0.6–0.7
pmol/mg of protein. Scatchard plots of [3H]ryanodine binding to
cardiac WT and mutant receptors showed similar Bmax values
and no differences in Kd values (n 
 4, mean Kd 	 S.E.:
WT-RyR2, 5.2 	 1.5 nM; RyR2-S2809A, 6.9 	 1.8 nM; RyR2-
S2809D, 5.9 	 2.3 nM; data not shown).
RyR Phosphorylation Mutants Bind FKBP—Marks and col-
leagues (9, 23) have shown that PKA-mediated hyperphospho-
rylation of skeletal and cardiac RyRs is associated with the
dissociation of the small FKBPs. To determine whether the
serine to alanine and aspartic acid mutants bound FKBP, we
performed co-immunoprecipitation experiments. Recombinant
WT and mutant RyR2s co-expressed with FKBP12.6 were sol-
ubilized in Triton X-100 as described under “Experimental
Procedures,” and the non-solubilized material was removed by
centrifugation. RyR2s in the total and supernatant fractions
were immunoprecipitated using anti-RyR2 antibody and ana-
lyzed by Western blots for RyR2 (Fig. 1A) and FKBP12.6 (Fig.
1B). Immunoprecipitates of the total and supernatant fractions
yielded immunoreactive bands for both RyR2 and FKBP. The
RyR Phosphorylation Mutants 51695
total fractions (one-fifth the volume of supernatant samples)
displayed higher signals than the supernatants, indicating that
only a partial solubilization of the RyRFKBP complexes had
occurred. Fig. 1C summarizes results from five independent
co-immunoprecipitation experiments using the supernatant
fractions. The intensity of the RyR and FKBP bands and their
ratio relative to WT-RyR1 and WT-RyR2 were determined. The
skeletal and cardiac phosphorylation mutants showed no sig-
nificant alterations in their FKBP/RyR binding ratio. In sepa-
rate co-immunoprecipitation experiments using skeletal and
cardiac SR vesicles and the recombinant WT-RyRs, similar
relative FKBP/RyR ratios were obtained (data not shown). In
control experiments, the use of agarose beads without addition
of anti-RyR antibody or of non-transfected or vector-only-trans-
fected cells or preincubation for 1 h at 37 °C with 10 M FK506
resulted in no detectable FKBP signals (not shown).
Mutation of the Phosphorylation Sites RyR1-Ser-2843 and
RyR2-Ser-2809 Does Not Affect Channel Function—The func-
tional properties of WT and mutant RyRs were determined in
single channel measurements using the planar lipid bilayer
method. Fig. 2A shows representative traces from WT-RyR1,
RyR1-S2843A, and RyR1-S2843D. Channels were recorded in
the presence of 2 M free Ca2 on both sides of the bilayer at
20-mV holding potential with K as conducting ion (top
traces). Under this condition, both the open probability (Po) and
gating of the mutant channels were indistinguishable from the
WT receptor. The mutant and WT-RyR1 channels were also
recorded under more physiological conditions at 0-mV holding
potential and using 10 mM luminal Ca2 as conducting ion
(bottom traces). In these recordings, the cytosolic free Ca2
levels were lowered to 100 nM, and 1 mM ATP was added to the
cis chamber. Again no significant differences were observed
between WT and mutant receptors. Representative current
histograms obtained from 2-min recordings of WT-RyR1 (left),
RyR1-S2843A (middle), and RyR1-S2843D (right) with 10 mM
Ca2 as current carrier are shown in Fig. 2B. Histogram anal-
ysis indicated a main current amplitude of  2.5 pA for WT and
mutant channels. The occurrence of currents with lower am-
plitudes indicated the presence of subconductances or poorly
resolved events. No significant differences in frequency or ap-
pearance of these events were observed between the WT and
mutant RyR1 channels.
Fig. 3, A and B, shows the corresponding single channel
recordings and current histograms for cardiac RyR channels
that were co-expressed with FKBP12.6. The left column shows
two representative WT current traces, and the middle and
right columns show those for the RyR2-S2809A and RyR2-
S2809D mutants, respectively. Channels were recorded with
K (top traces) at 20-mV holding potential or with Ca2
(bottom traces) as current carrier at 0-mV holding potential.
Similar to RyR1, the current traces and current histograms of
WT and the mutant channels did not show major differences.
The paucity of currents with a lower amplitude than the main
amplitude of 2.5 pA indicated that subconductances were
largely absent with 10 mM Ca2 as current carrier.
The averaged open probability (Po), number of events, and
mean open (To) and close (Tc) times are shown in Table I for
RyR1 and in Table II for RyR2. Po values were determined
using single and multiple channel recordings, whereas only
single channel recordings were used for number of events, To,
and Tc calculations. Some differences were observed between
the kinetic parameters of the WT-RyRs and their correspond-
ing phosphorylation mutants, but none of these were signifi-
cant. The K-conducting WT-RyR2, RyR2-S2809A, and RyR2-
S2809D channels recorded at 20-mV holding potential (top
panel of Table II) were activated to a greater extent with 2 M
Ca2 on both sides of the bilayer, and the open times were more
than 10-fold greater than those of the RyR1 channels (top panel
of Table I). These isoform-dependent differences are a charac-
teristic property of the two RyRs.
The functional properties of WT and mutant RyRs were also
compared in [3H]ryanodine binding experiments. Fig. 4A shows
the results of experiments investigating the regulation of skel-
etal WT and mutant RyRs by Ca2. Similar experiments were
also performed with cardiac WT and mutant RyRs transiently
co-expressed with FKBP12.6 in HEK293 cells (Fig. 4B).
[3H]Ryanodine binding resulted in similar, overlapping Ca2
activation/Ca2 inactivation curves for WT-RyR1 and the two
RyR1 mutants (Fig. 4A) and WT-RyR2 and the two RyR2
mutants (Fig. 4B). WT and mutant receptors showed a similar
Ca2 dependence under oxidizing (1 mM GSSG, Fig. 4, A and B)
and reducing (5 mM GSH, not shown) conditions.
Phosphorylation of RyR by either PKA or CaMKII has been
reported to attenuate Mg2 inhibition of channel activity (15,
20, 36). We determined whether Mg2 differentially inhibited
the two RyR2 phosphorylation mutants. Recombinant WT and
mutant RyR2s were incubated in a 0.15 M KCl buffer contain-
ing 1.4 mM Ca2 and Mg2 concentrations ranging from 0 to 10
mM. Increases in Mg2 concentration resulted in a progressive
decrease in [3H]ryanodine binding, however, without signifi-
cant differences between WT and mutant RyR2s (Fig. 5A).
Similarly 5 mM AMP-PCP, a non-hydrolyzable ATP analog, in
the presence of 0.65 and 4 mM Ca2 caused no significant
FIG. 1. Skeletal and cardiac RyR phosphorylation mutants
bind FKBP. Membrane fractions containing recombinant WT and
mutant channels were solubilized in 2.5% Triton X-100 and 1 M NaCl,
and co-immunoprecipitation was performed using total (T, one-fifth the
volume of supernatant) and supernatant (SN) fractions. A, immunoblot
following immunoprecipitation of WT-RyR2 (WT), RyR2-S2809A (SA),
and RyR2-S2809D (SD) from both total and supernatant fractions. B,
immunoblot showing the pulled down FKBP from the same gel. C,
pooled and normalized results from five co-immunoprecipitation exper-
iments using supernatant fractions. Data are given as mean 	 S.E. No
significant differences within the skeletal or cardiac groups were ob-
served. Norm., normalized.
RyR Phosphorylation Mutants51696
changes in Mg2 inhibition between mutant and WT receptors
(Fig. 5B).
We also considered the possibility that the recombinant RyR
channels with a serine to aspartic acid substitution decreased
the Ca2 content of HEK293 cells by forming “leaky” Ca2
channels (9, 23). In Fig. 6, intracellular Ca2 release in re-
sponse to a bolus of 10 mM caffeine was determined by intra-
cellular fluo-4 fluorescence. The recordings in five representa-
tive, individual cells expressing WT-RyR1 are shown in Fig. 6A.
Caffeine (10 mM) caused a rapid increase in free Ca2 as indi-
cated by the 2–3-fold rise in fluo-4 fluorescence from base-line
levels that abated in 60 s. Peak caffeine responses were
normalized by permeabilizing the cells to Ca2 (2 mM) present
in KRH. Addition of the Ca2 ionophore ionomycin increased
the fluorescence intensities proportional to those observed with
caffeine. Only cells showing a 1.5-fold increase in fluores-
cence in response to caffeine addition (typically 40–50%) were
included in the analysis. Fig. 6B summarizes the results from
at least two separate cell preparations and combines data from
15–27 cells expressing skeletal WT and mutant RyRs and
22–44 cells expressing cardiac WT and mutant RyRs. For both
isoforms, no significant differences in the size of the caffeine-
sensitive Ca2 stores were observed between WT and mutants.
Dephosphorylation of Ser-2809 Does Not Affect Calcium Re-
sponse of Canine SR—Dephospho-Ser-2809 and phospho-Ser-
2809 antibodies were used to determine the level of RyR2-Ser-
2809 phosphorylation in cardiac SR membranes. Fig. 7 (inset)
shows a strong RyR2-immunoreactive band using the phospho-
Ser-2809 antibody. A weak signal was detected using the dephos-
pho-Ser-2809 antibody. Acid phosphatase treatment almost com-
pletely abolished phospho-Ser-2809 immunoreactivity while
causing an 4-fold increase in the dephospho-Ser-2809 signal. The
functional consequences of Ser-2809 dephosphorylation were ex-
amined in [3H]ryanodine binding measurements. Fig. 7 shows es-
sentially identical Ca2 activation/Ca2 inactivation binding
curves for cardiac SR membranes that were treated and not treated
with acid phosphatase. Alkaline phosphatase treatment also was
without significant effect on Ca2 dependence of treated SR (data
not shown).
Evidence for Additional Phosphorylation Sites in RyR2—We
also explored the possibility that additional sites in RyR are
phosphorylated. Mutant and WT cardiac receptors were ex-
pressed in the presence of 32Pi and isolated using a CaM-
agarose batch purification protocol. Proteins retained on the
beads were separated by 3–10% SDS-PAGE. Western blots of
unlabeled samples showed that solubilized native and recom-
binant RyR2s bind to the CaM-agarose beads (Fig. 8A). Addi-
tion of 3 M CaM abolished binding, thereby confirming the
specificity of the CaM and RyR interaction. Fig. 8B shows the
silver-stained gels of metabolically labeled WT-RyR2, RyR2-
S2809A, and RyR2-S2809D. RyR2s were bound in the presence
and absence of 3 M CaM to correct for nonspecific binding. The
corresponding autoradiogram is shown in Fig. 8C; WT and
mutant RyR2s all incorporated 32Pi radioactivity. The amount
of radioactivity in the RyR band was measured in a scintilla-
tion counter, normalized for the RyR2 content as determined by
FIG. 2. Single channel measurements of skeletal WT and mutant RyRs. A, membrane fractions containing WT and mutant RyR1s were
added to the cis site of a lipid bilayer. Shown is one representative single channel recording for each of the following: WT-RyR1 (left column),
RyR1-S2843A (middle column), and RyR1-S2843D (right column). Single channel currents shown as downward deflections from the closed levels
(C–) were recorded at 20-mV holding potential in symmetric 250 mM KCl, 20 mM KHepes, pH 7.4 in the presence of 2 M free cytosolic Ca2 (top
traces). Channels were also recorded under more physiological, submaximal Ca2-activating conditions at 0 mV in symmetrical 250 mM KCl with
10 mM luminal Ca2 in the presence of 1 mM cytosolic ATP and 100 nM cytosolic free Ca2 (bottom traces). B, representative current histograms
derived from 2-min recordings in the presence of 1 mM ATP and 100 nM free Ca2 with 10 mM luminal Ca2 as conducting ion.
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the silver staining and Western blot signals, and corrected for
32P background counts. The combined results from two inde-
pendent experiments are shown in Fig. 8D. The finding of
significant 32Pi incorporation into the cardiac phosphorylation
mutants suggests that RyR2 is phosphorylated at additional, so
far uncharacterized phosphorylation sites. We note that in our
experiments no attempt was made to activate CaMK or PKA,
which could have altered the extent of phosphorylation of Ser-
2809 relative to the additional sites.
DISCUSSION
Protein phosphorylation is a fundamental mechanism by
which kinases and phosphatases regulate a wide variety of
biological processes. In striated muscle, protein kinases and
phosphatases modulate both contraction and relaxation by
phosphorylating and dephosphorylating numerous SR proteins
that include the luminal Ca2-binding protein calsequestrin
(37), the Ca2 pump (38), its regulatory protein phospholam-
ban (39), the RyR-associated proteins triadin (40, 41) and sor-
cin (42), and the Ca2 release channel/ryanodine receptor (11).
Changes in the phosphorylation levels are of interest due to
the possibility that these contribute to an impaired SR and
contractile function during heart failure. PKA and CaMKII
phosphorylation of phospholamban results in an increased
Ca2-ATPase activity (39). Perturbation of regulation of phos-
pholamban phosphorylation by second messengers (39), along
with other cellular changes, has been suggested as one possible
mechanism leading to heart failure (25, 26). A second proposed
mechanism is that PKA-mediated hyperphosphorylation of a
conserved serine, Ser-2843 in the skeletal RyR and Ser-2809 in
cardiac RyR, contributes to an impaired SR and aberrant con-
TABLE I
Steady-state and kinetic single channel parameters for skeletal wild type RyR and phosphorylation mutants
Channel open probability (Po) was determined from single and multiple channel recordings of 2-min duration. Number of events and mean open
(To) and mean close (Tc) times were calculated from 2-min recordings of single channel activities. Results are given as the mean 	 S.E. with the
number of experiments in parentheses. HP, holding potential.
Po Events/min To Tc
ms ms
2 M Ca2 cis and trans, HP 
 20 mV
WT-RyR1 0.029 	 0.007 (10) 5,482 	 2,068 (5) 0.41 	 0.03 (5) 55.52 	 25.08 (5)
RyR1-S2843A 0.156 	 0.075 (11) 10,399 	 3,508(4) 0.53 	 0.10 (4) 14.96 	 5.02 (4)
RyR1-S2843D 0.030 	 0.009 (9) 7,072 	 1,962(6) 0.40 	 0.05 (6) 22.53 	 4.73 (6)
0.1–0.3 M Ca2  1 mM ATP cis, 10 mM
Ca2 trans, HP 
 0 mV
WT-RyR1 0.200 	 0.055 (10) 3,355 	 862 (5) 5.50 	 1.50 (5) 44.72 	 20.07 (5)
RyR1-S2843A 0.150 	 0.030 (11) 2,881 	 1,579(4) 3.20 	 0.59 (4) 120.11 	 64.51 (4)
RyR1-S2843D 0.121 	 0.030 (9) 2,760 	 560 (6) 4.30 	 0.62 (6) 48.93 	 16.14 (6)
FIG. 3. Single channel measurements of cardiac WT and mutant RyRs. A, membrane fractions containing WT-RyR2, RyR2-S2809A, and
RyR2-S2809D and co-expressed FKBP12.6 were added to the cis site of a lipid bilayer. Shown is one representative single channel recording for
each of the following: WT-RyR2 (left column), RyR2-S2809A (middle column), and RyR2-S2809D (right column). Single channel currents shown as
downward deflections from the closed levels (C–) were recorded as in Fig. 2. B, representative current histograms derived from 2-min recordings
in the presence of 1 mM ATP and 100 nM free Ca2 with 10 mM luminal Ca2 as conducting ion.
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tractile function during heart failure (9, 23). Following acute
ischemic/reperfusion decreased RyR2 phosphorylation levels
have been observed (43). In this study, we prepared two skel-
etal muscle and cardiac muscle RyR mutants to test the hy-
pothesis that phosphorylation of RyR1-Ser-2843 and RyR2-Ser-
2809 modifies the intrinsic channel properties of the two
receptor isoforms.
RyRs are known to be regulated by a large number of exog-
enous and endogenous effectors and to undergo various post-
translational modifications, including phosphorylation. The cy-
toplasmic assembly makes up 80% of the entire channel and
contains many conserved, potential phosphorylation sites. One
of these sites, RyR1-Ser-2843, and the corresponding serine in
the cardiac receptor, RyR2-Ser-2809, were phosphorylated by
cAMP- and CaM-dependent protein kinases (12, 14). However,
the presence of additional phosphorylation sites is likely as
CaMKII has been shown to phosphorylate one or more threo-
TABLE II
Steady-state and kinetic single channel parameters for cardiac wild type RyR and phosphorylation mutants
Channel open probability (Po) was determined from single and multiple channel recordings of 2-min duration. Number of events and mean open
(To) and mean close (Tc) times were calculated from 2-min recordings of single channel activities. Results are given as the mean 	 S.E. with the
number of experiments in parentheses. HP, holding potential.
Po Events/min To Tc
ms ms
2 M Ca2 cis and trans, HP 
 20 mV
WT-RyR2 0.497 	 0.072 (10) 11,305 	 2,982(4) 7.86 	 3.91 (4) 6.29 	 2.51 (4)
RyR2-S2809A 0.359 	 0.060 (9) 11,247 	 3,714(5) 6.87 	 2.17 (5) 30.87 	 25.55 (5)
RyR2-S2809D 0.505 	 0.071 (10) 7,578 	 1,938(4) 10.08 	 3.85 (4) 8.69 	 4.11 (4)
0.1–0.3 M Ca2  1 mM ATP cis, 10 mM
Ca2 trans, HP 
 0 mV
WT-RyR2 0.260 	 0.090 (8) 342 	 121 (4) 140 	 82 (4) 436 	 297 (4)
RyR2-S2809A 0.330 	 0.089 (9) 384 	 132 (5) 107 	 56 (5) 446 	 242 (5)
RyR2-S2809D 0.186 	 0.044 (10) 296 	 69 (4) 62 	 24 (4) 448 	 203 (4)
FIG. 4. Ca2 dependence of skeletal and cardiac WT and mu-
tant RyRs. A, skeletal WT-RyR (circles), RyR1-S2843A (triangles), and
RyR1-S2843D (inverted triangles) were incubated with 2.5 nM [3H]ry-
anodine in 20 mM KPipes, pH 7.0 buffer containing 0.15 M KCl, 1 mM
GSSG, and the indicated free [Ca2]. B, corresponding experiments
using cardiac WT-RyR (circles), RyR2-S2809A (triangles), and RyR2-
S2809D (inverted triangles) all co-expressed with FKBP12.6. Data are
mean 	 S.E. of 5–14 duplicate experiments.
FIG. 5. Mg2 dependence of cardiac WT and mutant RyR2s. A,
membranes containing WT-RyR2 (circles), RyR2-S2809A (triangles),
and RyR2-S2809D (inverted triangles) co-expressed with FKBP12.6
were incubated with 2.5 nM [3H]ryanodine in buffer containing 0.15 M
KCl, 20 mM KPipes, pH 7.0 in the presence of 1.4 mM Ca2 and 1 mM
GSSG. Addition of the indicated [Mg2] caused a progressive decrease
in bound [3H]ryanodine. Data are the mean 	 S.E. of 11 experiments. B,
membranes were assayed as in A in the presence of 5 mM AMP-PCP and
the indicated [Ca2] and [Mg2]. No significant difference between the
modulation of WT-RyR2 (no lines), RyR2-S2809A (single lines), and
RyR2-S2809D (crossed lines) were observed at either 0.65 mM Ca2 or 4
mM free Ca2. Data are the mean 	 S.E. of 5–10 experiments.
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nine residues in RyR (14). In support of these findings are
several studies observing different functional effects for PKA-
and CaMKII-phosphorylated RyRs (15, 44) and in vitro phos-
phorylation assays using phosphorylation state-dependent an-
tibodies that have suggested the presence of at least four
CaMK phosphorylation sites in addition to RyR2-Ser-2809 (16).
Our finding that the two RyR2-Ser-2809 mutants with a serine
to alanine or aspartic acid substitution incorporate 32Pi in
metabolic labeling experiments confirms the earlier findings
and indicates that the receptor may be phosphorylated in vivo
at more than one site. In vitro phosphorylation studies have
also indicated that protein kinase C and protein kinase G
phosphorylate RyR1 (14); however, regulation of the receptor
by these kinases under physiological conditions remains to be
established.
RyR1 and RyR2 are part of a multiprotein complex that
includes the tightly associated FK506-binding proteins (9, 23).
FK506 and rapamycin released FKBP12 from the RyR1 com-
plex and FKBP12.6 from the RyR2 complex and modulated
channel gating by increasing channel activity and inducing
FIG. 6. Wild type and mutant RyRs exhibit similar caffeine
response in situ. A, time histogram showing the response of five
individual fluo-4-loaded cells expressing WT-RyR1 to 10 mM caffeine
and subsequent ionomycin treatment. B, normalized caffeine response
of WT-RyR1 (WT), RyR1-S2843A (SA), RyR1-S2843D (SD), and their
cardiac equivalents co-expressed with FKBP12.6. Results are given as
mean 	 S.E. of at least 15 cells from two independent experiments for
WT and mutant RyRs. No significant differences were observed. R.U.,
response units; Norm., normalized.
FIG. 7. Dephosphorylation of RyR2-Ser-2809 has no effect on
Ca2 dependence. Non-treated (filled circles) and phosphatase-
treated (open circles) SR membranes were incubated with 2.5 nM [3H]ry-
anodine in 20 mM KPipes, pH 7.0 buffer containing 0.15 M KCl, 1 mM
GSSG, and the indicated free [Ca2]. Data are mean 	 S.E. of six
duplicate experiments. The inset shows an immunoblot using anti-
phospho- and anti-dephospho-RyR2-Ser-2809 antibody of 10 g of SR
with () or without (-) acid phosphatase treatment. Incubation for 1 h
at 37 °C caused dephosphorylation at RyR2-Ser-2809 as indicated by a
decrease in phospho- and an increase in dephospho-RyR2-Ser-2809
signal. PP, protein phosphatase; P-, phospho-; DeP-, dephospho-.
FIG. 8. RyR2 is phosphorylated at additional sites besides Ser-
2809. Membrane fractions obtained from 32Pi metabolically labeled
HEK293 cells expressing cardiac WT and mutant RyR2s were solubi-
lized in 2.5% Triton X-100 and 1 M NaCl in the presence of protein
phosphatase inhibitors and purified using CaM-agarose beads. A, rep-
resentative Western blot showing CaM batch-purified unlabeled WT-
RyR2, RyR2-S2809A, and RyR2-S2809D in the presence and absence of
3 M CaM. B, silver-stained gels of parallel processed 32P-labeled sam-
ples. The identified position of RyR2 in Western blots correlated with a
single high molecular weight band observed in silver-stained gels. C,
representative autoradiogram depicting levels of 32P incorporation in
WT-RyR2, RyR2-S2809A, and RyR2-S2809D protein bands. D, normal-
ized RyR2 32P incorporation of mutant receptors relative to WT-RyR2.
Results are mean 	 S.E. of two experiments combining data obtained
with RyR2-S2809A and RyR2-S2809D. card., cardiac.
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frequent subconductances in lipid bilayers (Ref. 45 but see also
Ref. 46). PKA-mediated RyR phosphorylation has been re-
ported to also be associated with the release of the FKBPs from
the RyR protein complexes and increased channel activities in
lipid bilayers. Moreover, Marks and colleagues (9, 23) found
that RyR1 from skeletal muscle and RyR2 from hearts of ani-
mal models of heart failure and human failing hearts are
hyperphosphorylated, are depleted of the FKBPs, and exhibit
increased channel activities. These findings led them to pro-
pose that hyperphosphorylated RyRs are leaky and therefore
lead to a reduced SR Ca2 load and impaired contractile func-
tion in heart failure. Marks and colleagues also characterized
three recombinant RyR phosphorylation mutants (RyR1-
S2843A, RyR1-S2843D, and RyR2-S2809D) following transient
expression in HEK293 cells (23, 47). The RyR1-S2843A mutant
in lipid bilayer measurements exhibited a single channel be-
havior similar to WT-RyR1 as observed in the present study.
However, different results were obtained with the recombinant
RyR1-S2843D and RyR2-S2809D mutants with the RyR2-
S2809D mutants showing a more than 2-fold increase in open
probability compared with WT receptor and the RyR1-S2843D
mutation causing an 100-fold increase in channel activity.
The recordings showed an increase in the number of channel
events, and current histograms indicated the appearances of sub-
states similar to those observed in native, PKA-phosphorylated
RyR.
In this study, we found that in single channel measurements
Po values, frequency of full open events and substates, and
mean open and closed times were not significantly different for
WT and mutants for both the skeletal and cardiac RyR iso-
forms. We also analyzed Ca2-mediated activation and inacti-
vation of WT and mutant receptors in [3H]ryanodine binding
experiments as well as the caffeine response of transiently
expressed WT and mutant receptors in calcium imaging exper-
iments. In both assays, we were unable to detect an increased
activity of the RyR1-S2843D or RyR2-S2809D mutants over
that of WT. Marks and colleagues (23, 47) used co-immunopre-
cipitation experiments to also show that RyR1-S2843D and
RyR2-S2809D lost their ability to bind FKBP12. Loss of this
accessory protein in the mutant and hyperphosphorylated na-
tive RyRs was suggested to account for the observed changes in
channel gating. Indeed rebinding of a “sticky” FKBP12.6-D37S
mutant that was able to bind to the phosphorylated RyR2
restored normal RyR2-S2809D channel function. Our co-immu-
noprecipitation data showed that RyR1-S2843D and RyR2-
S2809D bind the FKBPs to an extent similar to WT, RyR1-
S2843A, and RyR2-S2809A receptors. Differences in the
experimental conditions may account for the differences in
FKBP binding observed by Marks and colleagues and the pres-
ent study. To ensure that the immunoprecipitated FKBPs did
not bind to other proteins present in the membrane fractions,
we performed co-immunoprecipitation experiments with
100,000  g supernatant fractions. High salt (1 M NaCl) and
detergent (2.5% Triton X-100) concentrations were required to
solubilize WT and mutant receptors. RyR solubilization for 12 h
at 4 °C in modified radioimmune precipitation assay buffer and
low salt concentrations (154 mM NaCl), conditions used by
Reiken et al. (23) for skeletal and by Marx et al. (9) for cardiac
RyR, resulted in an only small extent of RyR solubilization in
our experiments.
Back-phosphorylation (48) and the use of phosphorylation
state-dependent antibodies (Ref. 16 and this study) indicate
that cardiac SR exhibits substantial endogenous phosphoryla-
tion levels at RyR2-Ser-2809. Treatment of cardiac SR with
acid phosphatase (Fig. 7) and alkaline phosphatase (data not
shown) caused dephosphorylation of RyR2-Ser-2809 without
affecting RyR2 activity in [3H]ryanodine binding experiments.
This observation is in agreement with the finding of a similar
regulation of our mutants, which mimic the phosphorylated
and dephosphorylated receptors.
In conclusion, in this study we tested the hypothesis of
Marks and colleagues (9, 23) that PKA-mediated hyperphos-
phorylation of a conserved serine, Ser-2843 in skeletal RyR and
Ser-2809 in cardiac RyR, results in an aberrant SR function
during heart failure. We found that substitution of Ser-2809 in
RyR2 and Ser-2843 in RyR1 with an aspartic acid neither
resulted in the release of the associated FK506-binding pro-
teins nor modified the intrinsic channel properties of the two
receptor isoforms. Further studies are necessary that are be-
yond the scope of this work to clarify the role of protein phos-
phorylation on RyR2 function in normal and failing hearts.
These include the possibility that phosphorylation of the RyRs
at additional sites may alter intrinsic RyR function as well as
affect the binding of RyR accessory proteins such as the
FKBPs.
Acknowledgment—We thank Daniel A. Pasek for preparing the car-
diac and skeletal muscle membrane fractions.
REFERENCES
1. Rios, E., and Pizarro, G. (1991) Physiol. Rev. 71, 849–908
2. Fabiato, A. (1983) Am. J. Physiol. 245, C1–C14
3. Franzini-Armstrong, C., Protasi, F., and Ramesh, V. (1999) Biophys. J. 77,
1528–1539
4. Franzini-Armstrong, C., and Protasi, F. (1997) Physiol. Rev. 77, 699–729
5. Fill, M., and Copello, J. A. (2002) Physiol. Rev. 82, 893–922
6. Brillantes, A. B., Ondrias, K., Scott, A., Kobrinsky, E., Ondriasova, E., Mos-
chella, M. C., Jayaraman, T., Landers, M., Ehrlich, B. E., and Marks, A. R.
(1994) Cell 77, 513–523
7. Marx, S. O., Ondrias, K., and Marks, A. R. (1998) Science 281, 818–821
8. Marx, S. O., Gaburjakova, J., Gaburjakova, M., Henrikson, C., Ondrias, K.,
and Marks, A. R. (2001) Circ. Res. 88, 1151–1158
9. Marx, S. O., Reiken, S., Hisamatsu, Y., Jayaraman, T., Burkhoff, D., Rosem-
blit, N., and Marks, A. R. (2000) Cell 101, 365–376
10. Bandyopadhyay, A., Shin, D. W., Ahn, J. O., and Kim, D. H. (2000) Biochem.
J. 352, 61–70
11. Meissner, G. (2002) Front. Biosci. 7, d2072–d2080
12. Witcher, D. R., Kovacs, R. J., Schulman, H., Cefali, D. C., and Jones, L. R.
(1991) J. Biol. Chem. 266, 11144–11152
13. Chu, A., Sumbilla, C., Inesi, G., Jay, S. D., and Campbell, K. P. (1990)
Biochemistry 29, 5899–5905
14. Suko, J., Maurer, F. I., Plank, B., Bertel, O., Wyskovsky, W., Hohenegger, M.,
and Hellmann, G. (1993) Biochim. Biophys. Acta 1175, 193–206
15. Hain, J., Onoue, H., Mayrleitner, M., Fleischer, S., and Schindler, H. (1995)
J. Biol. Chem. 270, 2074–2081
16. Rodriguez, P., Bhogal, M. S., and Colyer, J. (2003) J. Biol. Chem. 278,
38593–38600
17. Hohenegger, M., and Suko, J. (1993) Biochem. J. 296, 303–308
18. Dulhunty, A. F., Laver, D., Curtis, S. M., Pace, S., Haarmann, C., and Gallant,
E. M. (2001) Biophys. J. 81, 3240–3252
19. Bayer, K. U., Harbers, K., and Schulman, H. (1998) EMBO J. 17, 5598–5605
20. Uehara, A., Yasukochi, M., Mejia-Alvarez, R., Fill, M., and Imanaga, I. (2002)
Pflueg. Arch. Eur. J. Physiol. 444, 202–212
21. Valdivia, H. H., Kaplan, J. H., Ellis-Davies, G. C., and Lederer, W. J. (1995)
Science 267, 1997–2000
22. Ward, C. W., Reiken, S., Marks, A. R., Marty, I., Vassort, G., and Lacampagne,
A. (2003) FASEB J. 17, 1517–1519
23. Reiken, S., Lacampagne, A., Zhou, H., Kherani, A., Lehnart, S. E., Ward, C.,
Huang, F., Gaburjakova, M., Gaburjakova, J., Rosemblit, N., Warren, M. S.,
He, K. L., Yi, G. H., Wang, J., Burkhoff, D., Vassort, G., and Marks, A. R.
(2003) J. Cell Biol. 160, 919–928
24. Yano, M., Ono, K., Ohkusa, T., Suetsugu, M., Kohno, M., Hisaoka, T., Koba-
yashi, S., Hisamatsu, Y., Yamamoto, T., Noguchi, N., Takasawa, S., Oka-
moto, H., and Matsuzaki, M. (2000) Circulation 102, 2131–2136
25. Jiang, M. T., Lokuta, A. J., Farrell, E. F., Wolff, M. R., Haworth, R. A., and
Valdivia, H. H. (2002) Circ. Res. 91, 1015–1022
26. Li, Y., Kranias, E. G., Mignery, G. A., and Bers, D. M. (2002) Circ. Res. 90,
309–316
27. Gao, L., Tripathy, A., Lu, X., and Meissner, G. (1997) FEBS Lett. 412, 223–226
28. Nakai, J., Imagawa, T., Hakamata, Y., Shigekawa, M., Takeshima, H., and
Numa, S. (1990) FEBS Lett. 271, 169–177
29. Meissner, G. (1984) J. Biol. Chem. 259, 2365–2374
30. Meissner, G., and Henderson, J. S. (1987) J. Biol. Chem. 262, 3065–3073
31. Stange, M., Tripathy, A., and Meissner, G. (2001) Biophys. J. 81, 1419–1429
32. Sutko, J. L., Airey, J. A., Welch, W., and Ruest, L. (1997) Pharmacol. Rev. 49,
53–98
33. Balshaw, D. M., Xu, L., Yamaguchi, N., Pasek, D. A., and Meissner, G. (2001)
J. Biol. Chem. 276, 20144–20153
34. Fessenden, J. D., Wang, Y., Moore, R. A., Chen, S. R., Allen, P. D., and Pessah,
I. N. (2000) Biophys. J. 79, 2509–2525
35. Schoenmakers, T. J., Visser, G. J., Flick, G., and Theuvenet, A. P. (1992)
RyR Phosphorylation Mutants 51701
BioTechniques 12, 870–879
36. Hain, J., Nath, S., Mayrleitner, M., Fleischer, S., and Schindler, H. (1994)
Biophys. J. 67, 1823–1833
37. Szegedi, C., Sarkozi, S., Herzog, A., Jona, I., and Varsanyi, M. (1999) Biochem.
J. 337, 19–22
38. Narayanan, N., and Xu, A. (1997) Basic Res. Cardiol. 92, 25–35
39. Simmerman, H. K., and Jones, L. R. (1998) Physiol. Rev. 78, 921–947
40. Guo, W., Jorgensen, A. O., and Campbell, K. P. (1994) J. Biol. Chem. 269,
28359–28365
41. Damiani, E., Picello, E., Saggin, L., and Margreth, A. (1995) Biochem. Biophys.
Res. Commun. 209, 457–465
42. Lokuta, A. J., Meyers, M. B., Sander, P. R., Fishman, G. I., and Valdivia, H. H.
(1997) J. Biol. Chem. 272, 25333–25338
43. Temsah, R. M., Dyck, C., Netticadan, T., Chapman, D., Elimban, V., and
Dhalla, N. S. (2000) J. Pharmacol. Exp. Ther. 293, 15–23
44. Lokuta, A. J., Rogers, T. B., Lederer, W. J., and Valdivia, H. H. (1995)
J. Physiol. 487, 609–622
45. Gaburjakova, M., Gaburjakova, J., Reiken, S., Huang, F., Marx, S. O., Rosem-
blit, N., and Marks, A. R. (2001) J. Biol. Chem. 276, 16931–16935
46. Timerman, A. P., Onoue, H., Xin, H. B., Barg, S., Copello, J., Wiederrecht, G.,
and Fleischer, S. (1996) J. Biol. Chem. 271, 20385–20391
47. Wehrens, X. H., Lehnart, S. E., Huang, F., Vest, J. A., Reiken, S. R., Mohler,
P. J., Sun, J., Guatimosim, S., Song, L. S., Rosemblit, N., D’Armiento, J. M.,
Napolitano, C., Memmi, M., Priori, S. G., Lederer, W. J., and Marks, A. R.
(2003) Cell 113, 829–840
48. Zhang, T., Maier, L. S., Dalton, N. D., Miyamoto, S., Ross, J., Jr., Bers, D. M.,
and Brown, J. H. (2003) Circ. Res. 92, 912–919
RyR Phosphorylation Mutants51702
